Go Deep
Kaken Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,610 | 66.8 | 0.97 | 0.03 | 2,294.33 |
Kaken Pharmaceutical Co., Ltd. Quarterly Results
| Line Item | Jun 2025 |
|---|---|
| EPS | 7.1 |
Kaken Pharmaceutical Co., Ltd. Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 76,871,000,000.0 | 94,035,000,000.0 | 72,044,000,000.0 | 72,984,000,000.0 |
| Net Profit | 2,144,000,000.0 | 13,945,000,000.0 | 8,025,000,000.0 | 5,440,000,000.0 |
| EPS | 56.6 | 365.4 | 212.7 | 144.8 |
Kaken Pharmaceutical Co., Ltd. Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 178,217,000,000.0 | 193,377,000,000.0 | 171,623,000,000.0 | 166,328,000,000.0 | — |
| Total Liabilities | 30,600,000,000.0 | 40,743,000,000.0 | 27,868,000,000.0 | 29,493,000,000.0 | — |
| Total Equity | 147,617,000,000.0 | 152,634,000,000.0 | 143,755,000,000.0 | 136,257,000,000.0 | — |
Kaken Pharmaceutical Co., Ltd. Assets & Liabilities Breakdown (JPY millions)
What it owns — Mar 2026
Cash & short-term investments 28.5%Receivables 10.9%Inventory 10.7%Fixed assets (tangible) 15.2%Intangible assets 13.6%Long-term investments 10.5%Other assets 10.6%
How it's funded — Mar 2026
Short-term debt 2.2%Payables 4.2%Other liabilities 10.8%Shareholders' equity 82.8%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 50,705.0 | 70,085.0 | 65,324.0 | 74,260.0 |
| Receivables | 19,378.0 | 21,178.0 | 23,744.0 | 19,268.0 |
| Inventory | 19,115.0 | 19,020.0 | 17,167.0 | 15,563.0 |
| Fixed assets (tangible) | 27,134.0 | 27,629.0 | 25,355.0 | 25,498.0 |
| Intangible assets | 24,291.0 | 22,228.0 | 7,462.0 | 6,741.0 |
| Long-term investments | 18,730.0 | 18,875.0 | 20,532.0 | 17,511.0 |
| Other assets | 18,864.0 | 14,362.0 | 12,039.0 | 7,487.0 |
| Liabilities & equity | ||||
| Short-term debt | 3,850.0 | 3,850.0 | 3,850.0 | 3,850.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 7,428.0 | 8,186.0 | 6,976.0 | 6,130.0 |
| Other liabilities | 19,322.0 | 28,707.0 | 17,042.0 | 19,513.0 |
| Shareholders' equity | 147,617.0 | 152,634.0 | 143,755.0 | 136,835.0 |
| Net tangible assets | 123,326.0 | 130,406.0 | 136,293.0 | 129,516.0 |
Kaken Pharmaceutical Co., Ltd. Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -11,079,000,000.0 | 29,780,000,000.0 | 2,577,000,000.0 | 9,253,000,000.0 | — |
| Investing Activities | 315,000,000.0 | -19,650,000,000.0 | -5,854,000,000.0 | -2,627,000,000.0 | — |
| Financing Activities | -8,841,000,000.0 | -5,369,000,000.0 | -5,658,000,000.0 | -6,990,000,000.0 | — |